Clinical Trials in Rostov-on-Don, Russia

29 recruiting

Showing 120 of 24 trials

Recruiting

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

Rare DiseasesGeneralized Myasthenia Gravis (gMG)
AstraZeneca450 enrolled6 locationsNCT07247279
Recruiting
Phase 3

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled618 locationsNCT07517263
Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled175 locationsNCT01804686
Recruiting

ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia

AsthmaChronic Rhinosinusitis With Nasal Polyps (CRSwNP)
AstraZeneca110 enrolled11 locationsNCT07399665
Recruiting

Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

Breast Cancer
Novartis Pharmaceuticals2,766 enrolled39 locationsNCT06930859
Recruiting

Lysosomal Acid Lipase Deficiency in Risk Groups

Lysosomal Acid Lipase Deficiency
AstraZeneca1,200 enrolled4 locationsNCT07455864
Recruiting

The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia

Hypophosphatasia
AstraZeneca55 enrolled4 locationsNCT07390240
Recruiting

Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

Severe Asthma
AstraZeneca5,000 enrolled37 locationsNCT06472310
Recruiting

Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients

Myocardial Infarction
Novartis Pharmaceuticals300 enrolled16 locationsNCT07142265
Recruiting
Phase 3

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting

Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study

Uncontrolled Asthma
AstraZeneca9,000 enrolled47 locationsNCT06521229
Recruiting
Phase 2

Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis
R-Pharm International, LLC71 enrolled14 locationsNCT07517575
Recruiting
Phase 3

The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients

RhinosinusitisRhinosinusitis Acute
Materia Medica Holding552 enrolled44 locationsNCT06901297
Recruiting
Phase 3

Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years

Acute Respiratory Viral Infection
Materia Medica Holding374 enrolled35 locationsNCT06715891
Recruiting
Phase 3

Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children

Cough
Materia Medica Holding264 enrolled30 locationsNCT07171099
Recruiting

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia

Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
AstraZeneca2,000 enrolled41 locationsNCT05887011
Recruiting
Phase 3

Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia

Alzheimer Type Dementia
Bigespas LTD450 enrolled12 locationsNCT07251023
Recruiting
Phase 3

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Cancer
Bayer402 enrolled383 locationsNCT04464226
Recruiting
Phase 2

Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease

Crohn's Disease (CD)
Biocad204 enrolled20 locationsNCT07078994
Recruiting
Phase 2

Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis (UC)
Biocad198 enrolled20 locationsNCT07080034